What is Bremelanotide?
Bremelanotide is a prescription melanocortin agonist studied for a defined form of low sexual desire associated with distress. It is also known as PT-141.
Biological role or research focus
Melanocortin signaling and sexual desire.
Its defined clinical use should not be generalized to erectile dysfunction or sexual performance.
Role reference: MedlinePlus · Bremelanotide ↗
Names you may encounter
PT-141 · PT141 · Vyleesi
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Melanocortin receptor agonist
- Main research area
- Sexual desire and related distress
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Bremelanotide ↗
Quick answers
- Is Bremelanotide FDA approved?
- Yes. Vyleesi autoinjector (NDA 210557, approved June 2019) for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Source ↗
- Is Bremelanotide safe?
- Approved for low sexual desire in premenopausal women; nausea is very common, and it briefly raises blood pressure, so it is not for people with uncontrolled hypertension or heart disease. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Bremelanotide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Bremelanotide?
- Yes. Our records list 2 FDA actions naming it, most recently on August 24, 2026: FDA warning letter to a "research peptide" seller (Peptide Partners) naming "PT-141" (bremelanotide), SS-31 and tesamorelin as unapproved new drugs despite research-use-only labeling. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| RECONNECT (2019) | Human randomized trial | 1,267 premenopausal women randomized across two studies of hypoactive sexual desire disorder. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2019
RECONNECT
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
- Population / model
- 1,267 premenopausal women randomized across two studies of hypoactive sexual desire disorder.
- Study design
- Two double-blind 24-week studies comparing bremelanotide with placebo.
- Main finding
- Desire scores improved and distress scores decreased more with treatment. Nausea, flushing, and headache were more frequent.
- Limits & context
- The endpoints were validated symptom scales. These results do not establish treatment for every cause of low desire, male erectile dysfunction, or general sexual performance.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
10 registered studies name Bremelanotide as an intervention; 1 is recruiting or under way, 0 have not started recruiting yet and 9 completed. Checked November 14, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 10 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Bremelanotide. ↗
· 2012 · Review
Bremelanotide. ↗
· 2006 · Review
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. ↗
Journal of midwifery & women's health · 2021 Nov · Journal Article, Review
Read available full text ↗
Bremelanotide: First Approval. ↗
Drugs · 2019 Sep · Journal Article, Review
Risks & interactions
Approved for low sexual desire in premenopausal women; nausea is very common, and it briefly raises blood pressure, so it is not for people with uncontrolled hypertension or heart disease.
Safety comes from FDA-approved labeling (Vyleesi) based on two 24-week placebo-controlled trials in about 1,247 premenopausal women plus a 52-week open-label extension. Safety in other groups is not established by the label.
Take extra care with: Heart or blood pressure problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- People with uncontrolled high blood pressure
- People with known cardiovascular disease
- Not recommended for people at high risk of cardiovascular disease
Interactions
- Naltrexone taken by mouth: bremelanotide can sharply lower its levels, risking failure of alcohol or opioid addiction treatment
- Other oral medicines: slowed stomach emptying may delay or reduce absorption (for example, antibiotics or pain relievers)
Serious risks
- Temporary rise in blood pressure and drop in heart rate
- Patches of darkened skin on the face, gums or breasts that may not fully fade, more likely in people with darker skin
- Severe or persistent nausea, which led some trial participants to stop
Common side effects
- nausea
- flushing
- injection-site reactions
- headache
- vomiting
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Vyleesi (bremelanotide) prescribing information ↗
Key precautions
Nausea and flushing are common. Uncontrolled hypertension or heart disease are important exclusions. Skin darkening may persist, and effects on oral-medication absorption warrant attention.
Source: MedlinePlus · Bremelanotide ↗
Regulatory status
- U.S. FDA approval
- Approved
Vyleesi autoinjector (NDA 210557, approved June 2019) for acquired, generalized hypoactive sexual desire disorder in premenopausal women. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named. It has FDA approval, so S0 does not apply. source
FDA actions
- FDA warning letter to a "research peptide" seller (Peptide Partners) naming "PT-141" (bremelanotide), SS-31 and tesamorelin as unapproved new drugs despite research-use-only labeling. (2026-08-24) source
- FDA warning letter to a "research peptide" seller (NuScience Peptides) naming "PT-141 Peptide (Bremelanotide)" among other peptides as unapproved new drugs. (2026-08-24) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The cited medication reference describes acquired low desire in premenopausal women when another condition, relationship issue, or drug does not explain it. This is not a general sexual-performance or male erectile-dysfunction indication.
Source: MedlinePlus · Bremelanotide ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
It activates melanocortin pathways in the nervous system. The relevant clinical question is whether desire and associated distress improve, not whether it changes a reproductive-hormone blood test.
Source: MedlinePlus · Bremelanotide ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Its defined clinical use should not be generalized to erectile dysfunction or sexual performance.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Is PT-141 another name for bremelanotide?
Yes, it is a commonly used development name. The identity of an actual product still needs verification.
Source: MedlinePlus · Bremelanotide ↗
Did RECONNECT measure fertility?
No. Its primary outcomes concerned sexual desire and distress, not ovulation, pregnancy, or live birth.
References & editorial record
- MedlinePlus · Bremelanotide ↗
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Melanotan I vs Melanotan II: one became a medicine, one did not
Melanotan I and Melanotan II were developed in the same lab to darken skin, but only Melanotan I (afamelanotide) became an approved medicine, for a rare light-sensitivity disease. Melanotan II has only tiny early studies and documented safety concerns.
Read the guide →
